Niagen Bioscience, Inc. (NAGE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50M 100M 150M Q3 '21: 65.1M Q4 '21: 67.4M Q1 '22: 70M Q2 '22: 69.1M Q3 '22: 68.8M Q4 '22: 72M Q1 '23: 77.3M Q2 '23: 80.9M Q3 '23: 83.4M Q4 '23: 83.6M Q1 '24: 83.2M Q2 '24: 85.6M Q3 '24: 91.7M Q4 '24: 99.6M Q1 '25: 107.9M Q2 '25: 116.3M Q3 '25: 124.7M Q4 '25: 129.4M Q1 '26: 130.4M Q2 '26: 129.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 30M 60M 90M Q3 '21: 40M Q4 '21: 41.5M Q1 '22: 42.8M Q2 '22: 42M Q3 '22: 41.6M Q4 '22: 42.8M Q1 '23: 45.8M Q2 '23: 48.1M Q3 '23: 49.9M Q4 '23: 50.8M Q1 '24: 50.7M Q2 '24: 52.1M Q3 '24: 56.3M Q4 '24: 61.6M Q1 '25: 67.5M Q2 '25: 74M Q3 '25: 79.7M Q4 '25: 83.2M Q1 '26: 83.8M Q2 '26: 82.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-30M -20M -10M 0 10M 20M 30M Q3 '21: -27.8M Q4 '21: -27.1M Q1 '22: -27.4M Q2 '22: -28.3M Q3 '22: -22.5M Q4 '22: -18.6M Q1 '23: -12.9M Q2 '23: -8.8M Q3 '23: -6.9M Q4 '23: -5.6M Q1 '24: -4.4M Q2 '24: -2.3M Q3 '24: 447K Q4 '24: 7.7M Q1 '25: 13.2M Q2 '25: 16.7M Q3 '25: 19.3M Q4 '25: 16.3M Q1 '26: 13.1M Q2 '26: 10.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-30M -20M -10M 0 10M 20M 30M Q3 '21: -27.9M Q4 '21: -27.1M Q1 '22: -27.5M Q2 '22: -28.3M Q3 '22: -20.4M Q4 '22: -16.5M Q1 '23: -10.7M Q2 '23: -6.5M Q3 '23: -6.5M Q4 '23: -4.9M Q1 '24: -3.5M Q2 '24: -1.4M Q3 '24: 1.5M Q4 '24: 8.6M Q1 '25: 14.1M Q2 '25: 17.7M Q3 '25: 20.4M Q4 '25: 17.4M Q1 '26: 18.6M Q2 '26: 16M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 20M 40M 60M Q3 '21: 25.1M Q4 '21: 26M Q1 '22: 27.2M Q2 '22: 27M Q3 '22: 27.2M Q4 '22: 29.3M Q1 '23: 31.6M Q2 '23: 32.8M Q3 '23: 33.5M Q4 '23: 32.8M Q1 '24: 32.4M Q2 '24: 33.5M Q3 '24: 35.3M Q4 '24: 38M Q1 '25: 40.5M Q2 '25: 42.3M Q3 '25: 45M Q4 '25: 46.2M Q1 '26: 46.6M Q2 '26: 46.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-27M -18M -9M 0 9M 18M 27M Q3 '21: -19.2M Q4 '21: -24.2M Q1 '22: -26M Q2 '22: -21.9M Q3 '22: -19.7M Q4 '22: -15.1M Q1 '23: -5.1M Q2 '23: 2M Q3 '23: 6.1M Q4 '23: 7.1M Q1 '24: 4.6M Q2 '24: 1.1M Q3 '24: 4.2M Q4 '24: 12.1M Q1 '25: 19.7M Q2 '25: 21.2M Q3 '25: 21.4M Q4 '25: 13.5M Q1 '26: 4.4M Q2 '26: 5.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-27M -18M -9M 0 9M 18M 27M Q1 '16: -2.6M Q2 '16: -4.9M Q3 '16: -5.2M Q4 '16: -5.2M Q4 '16: -4.4M Q2 '17: -1.7M Q3 '17: -7.1M Q3 '17: -7.3M Q4 '17: -11M Q1 '18: -14.9M Q2 '18: -16.9M Q3 '18: -21.1M Q4 '18: -22.2M Q1 '19: -21.4M Q2 '19: -22.8M Q3 '19: -25.4M Q4 '19: -21.2M Q1 '20: -23.1M Q2 '20: -15.7M Q3 '20: -11.7M Q2 '16 Q4 '16 Q3 '17 Q2 '18 Q1 '19 Q4 '19 Q3 '20

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q3 '18: 55.1K Q2 '20: 60.9M Q3 '20: 61.7M Q1 '21: 64.2M Q2 '21: 68M Q3 '21: 68.2M Q1 '22: 68.3M Q2 '22: 68.3M Q3 '22: 68.3M Q1 '23: 74.8M Q2 '23: 75M Q3 '23: 75M Q1 '24: 75.2M Q2 '24: 75.6M Q3 '24: 77.8M Q1 '25: 83.2M Q2 '25: 86.2M Q3 '25: 86.6M Q1 '26: 84.6M Q2 '26: 82.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.45 -0.30 -0.15 0.00 0.15 0.30 0.45 Q3 '21: -0.43 Q4 '21: -0.40 Q1 '22: -0.39 Q2 '22: -0.40 Q3 '22: -0.28 Q4 '22: -0.23 Q1 '23: -0.15 Q2 '23: -0.09 Q3 '23: -0.09 Q4 '23: -0.07 Q1 '24: -0.05 Q2 '24: -0.02 Q3 '24: 0.01 Q4 '24: 0.10 Q1 '25: 0.17 Q2 '25: 0.21 Q3 '25: 0.24 Q4 '25: 0.20 Q1 '26: 0.21 Q2 '26: 0.18 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.